Literature DB >> 19551699

Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection.

Vincent Lo Re1, Kevin Haynes, Kimberly A Forde, A Russell Localio, Rita Schinnar, James D Lewis.   

Abstract

PURPOSE: Before using computerized databases to study hepatitis C virus (HCV) epidemiology, the validity of the diagnosis must be assessed. We determined the accuracy of HCV diagnostic codes within The Health Improvement Network (THIN), an electronic database containing medical record data from general medical practices in the United Kingdom.
METHODS: Patients with initial diagnostic codes for HCV infection and nonspecific viral hepatitis between 2000 and 2007 in the THIN database were identified. Questionnaires were mailed to general practitioners caring for a random sample of 150 of these patients (75 with an HCV code; 75 with a nonspecific viral hepatitis code) to collect information on HCV and other hepatitis diagnoses. We determined the positive predictive value of the database's HCV diagnostic codes and its ability to identify the date of a new HCV diagnosis.
RESULTS: Usable surveys were returned for 146 (97%) patients. Among 74 patients with an HCV code and questionnaire data, HCV was confirmed in 64 (positive predictive value, 86%; 95%CI, 77-93%). In 40 (63%), the first recorded diagnosis in THIN was within 30 days of the date reported in the questionnaire (median difference, 11 days; interquartile range, 0-362 days). Among 72 patients with a nonspecific viral hepatitis code, 16 (22%) had HCV, but manual review of the database's electronic records correctly identified 12/16 (75%).
CONCLUSIONS: In THIN, the HCV-specific diagnostic codes are highly predictive of HCV infection. After manual review, few patients with a nonspecific viral hepatitis code were misclassified as having HCV infection.

Entities:  

Mesh:

Year:  2009        PMID: 19551699      PMCID: PMC2735008          DOI: 10.1002/pds.1784

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  21 in total

1.  The prevalence of hepatitis C in England and Wales.

Authors:  M A Balogun; M E Ramsay; L M Hesketh; N Andrews; K P Osborne; N J Gay; P Morgan-Capner
Journal:  J Infect       Date:  2002-11       Impact factor: 6.072

2.  Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey.

Authors:  James D Lewis; Colleen Brensinger
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-07       Impact factor: 2.890

Review 3.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  The Read clinical classification.

Authors:  J Chisholm
Journal:  BMJ       Date:  1990-04-28

5.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

Authors:  James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

6.  The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Authors:  D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

7.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

8.  Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis.

Authors:  A M Di Bisceglie; Z D Goodman; K G Ishak; J H Hoofnagle; J J Melpolder; H J Alter
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

9.  The progression of HCV-associated liver disease in a cohort of haemophilic patients.

Authors:  P Telfer; C Sabin; H Devereux; F Scott; G Dusheiko; C Lee
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

10.  Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease.

Authors:  James D Lewis; Colleen Brensinger; Warren B Bilker; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Apr-May       Impact factor: 2.890

View more
  34 in total

1.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

2.  Temporal and within practice variability in the health improvement network.

Authors:  Kevin Haynes; Warren B Bilker; Tom R Tenhave; Brian L Strom; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-13       Impact factor: 2.890

3.  Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Authors:  Ronac Mamtani; Kevin Haynes; Warren B Bilker; David J Vaughn; Brian L Strom; Karen Glanz; James D Lewis
Journal:  J Natl Cancer Inst       Date:  2012-08-09       Impact factor: 13.506

4.  Case validation in research using large databases.

Authors:  Luis Alberto García Rodríguez; Ana Ruigómez
Journal:  Br J Gen Pract       Date:  2010-03       Impact factor: 5.386

5.  Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.

Authors:  Christopher G Rowan; Steven M Brunelli; Jeffrey Munson; James Flory; Peter P Reese; Sean Hennessy; James Lewis; Daniel Mines; Jeffrey S Barrett; Warren Bilker; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-03-16       Impact factor: 2.890

6.  Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK.

Authors:  Marcus Lind; Aldina Pivodic; Lucia Cea-Soriano; Olle Nerman; Nils-Gunnar Pehrsson; Luis A Garcia-Rodriguez
Journal:  Diabetologia       Date:  2014-05-09       Impact factor: 10.122

7.  Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom.

Authors:  M H Noe; S K Grewal; D B Shin; A Ogdie; J Takeshita; J M Gelfand
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-06-01       Impact factor: 6.166

Review 8.  Informatics and machine learning to define the phenotype.

Authors:  Anna Okula Basile; Marylyn DeRiggi Ritchie
Journal:  Expert Rev Mol Diagn       Date:  2018-02-16       Impact factor: 5.225

9.  Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study.

Authors:  Antonio Gonzalez-Perez; Raymond G Schlienger; Luis A García Rodríguez
Journal:  Diabetes Care       Date:  2010-09-10       Impact factor: 19.112

10.  Validating the extract, transform, load process used to populate a large clinical research database.

Authors:  Michael J Denney; Dustin M Long; Matthew G Armistead; Jamie L Anderson; Baqiyyah N Conway
Journal:  Int J Med Inform       Date:  2016-07-29       Impact factor: 4.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.